EXPERIMENTAL MYASTHENIA
\ɛkspˌɛɹɪmˈɛntə͡l mˌa͡ɪɐsθˈiːni͡ə], \ɛkspˌɛɹɪmˈɛntəl mˌaɪɐsθˈiːniə], \ɛ_k_s_p_ˌɛ_ɹ_ɪ_m_ˈɛ_n_t_əl m_ˌaɪ__ɐ_s_θ_ˈiː_n_iə]\
Sort: Oldest first
-
Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3)
By DataStellar Co., Ltd